Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance

Stock Track

2025/11/12

CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.

The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.

Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.

In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.

The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1180427284"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180427284\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180427284?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180427284","market":"hk","top_or_hot":-1,"title":"Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.</p>\n\n<p>The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.</p>\n\n<p>Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.</p>\n\n<p>In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.</p>\n\n<p>The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.</p>\n\n<p>The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.</p>\n\n<p>Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.</p>\n\n<p>In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.</p>\n\n<p>The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1180427284","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180427284","pubTimestamp":1762951706,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"股票追踪|CorMedix盘前飙升9.47%，因第三季度业绩出色并上调指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.\nThe biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.\nDriving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.\nIn light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.\nThe market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}